CSF1R kinase inhibitors and anti-CSF1R antibodies have been evaluated for therapeutic intervention in diseases where macrophages contribute to pathology, e.g., neurodegenerative disease, cancer, inflammation, and fibrosis [123•, 124]. Here, CSF1R is linked to cancer.